Reply  by Mosseri, Morris et al.
Renal Effect of Low-Dose
Dopamine in High-Risk
Patients Undergoing Coronary Angiography
Gare et al. (1) report no advantage of dopamine over “adequate
hydration” in patients with mild to moderate renal insufficiency
undergoing coronary angiography. The absence of a clinically
important effect is no surprise, for dopamine (2 mg/kg/min) would
not be a sufficient vasodilator to counteract such a potent renal
afferent arteriole vasoconstrictor as intrarenal adenosine. The
kidney responds to contrast media-induced osmotic stress with
afferent arteriolar vasoconstriction. This tubuloglomerular feed-
back response is largely mediated by adenosine, a mechanism that
has been confirmed by both animal and clinical studies (2–5). In
our randomized and blinded studies, the magnitude of adenosine
release and depression of creatinine clearance was proportional to
the osmolality of the contrast agent, essentially a dose-response
relation (2). It is attenuated by the adenosine receptor blocker
theophylline (3–5).
When pretreated with long-acting theophylline in addition to
hydration with D5W or half-normal saline, patients with moder-
ate renal dysfunction (creatinine #2.0 mg/dl) are reliably protected
from the nephrotoxic effects of contrast media (3–5). We currently
prescribe Theodur (3 mg/kg) orally the night before and b.i.d. the
day of angiography. It is critical that theophylline be administered
before contrast injection, but prolonged treatment after angiogra-
phy is unnecessary.
Theophylline prophylaxis to attenuate contrast-media nephro-
toxicity has not been adopted by cardiologists, perhaps because the
studies appeared in journals they do not normally read. Theoph-
ylline prophylaxis is effective, safe, and inexpensive. In view of the
magnitude of the clinical problem of contrast-media nephrotoxic-
ity, we wish to bring this therapeutic strategy to the attention of
the readers of JACC.
Richard E. Katholi, MD, FACC
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REPLY
Thank you for your interest in our article on the renal effect of
low-dose dopamine in high-risk patients undergoing coronary
angiography (1). We found no important renal protective effect of
dopamine in patients at high risk for contrast nephropathy (CN)
undergoing coronary angiography. We agree that the vasodilator
effect of low-dose dopamine may be too small to counteract the
afferent arteriolar vasoconstriction induced by the contrast me-
dium. Higher doses of dopamine, however, may contribute to even
more severe vasoconstriction.
We have also been interested in the adenosine receptor blocking
effect of theophylline. We found that the acute renal failure
induced by indomethacin and contrast medium in rats with
diabetes mellitus (DM) was mediated by adenosine via suppression
of renal and/or systemic NO2
2/NO3 production and that theoph-
ylline reversed NO2
2/NO3 secretion to levels similar to those of
DM rats (2). The role of theophylline as a means of reducing CN
in the clinical setting, however, is not well defined. Although
Katholi (3) and Kolonko (4) have found some beneficial effect of
theophylline, more recent studies focusing on higher-risk patients
failed to demonstrate such effect. Abizaid et al. (5) found that
neither aminophylline nor dopamine reduced the incidence of CN
compared with saline hydration alone, in patients with serum
creatinine $1.5 mg/dl. Erley et al. (whose previous study was cited
by Katholi and Taylor in their present Letter to the Editor)
randomized 80 patients with serum creatinine $1.5 mg/dl to
either 810 mg of theophylline daily or placebo (6). They found that
hydration alone was sufficient to preserve glomerular filtration and
that theophylline had no additional benefit; they suggested that
theophylline might be beneficial in patients for whom sufficient
hydration is difficult, such as patients with severe congestive heart
failure (6). Such patients, however, are usually treated with
multiple medications, and adding theophylline at a sufficient dose
may be accompanied by intolerable side effects.
Therefore, it seems to us that the advantages of theophylline in
reducing the detrimental effect of contrast media, especially in
high-risk patients, have yet to be proven. The prevention of CN in
patients receiving contrast media should be based, at the present
time, on adequate hydration accompanied by diuresis when
needed.
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Extraction Efficiency of
Extracellular MRI Contrast
Agents and Its Model-Dependent
Effects on Estimates of Myocardial Blood Flow
In their recent study, Cullen et al. (1) report on the highly relevant
determination of a perfusion reserve index with magnetic reso-
nance imaging (MRI) in patients with coronary artery disease.
Without wanting to detract from the fact that theirs is a valuable
study, we take issue with the negative appraisal of first-pass
imaging with rapid bolus injections.
Based on numerous studies with extravascular and intravascular
MRI contrast agents it has been shown that the best sensitivity to
changes in myocardial blood flow is observed with a rapid bolus
injection and imaging during the initial wash-in of contrast agent
(2). The investigators suggest that a slower injection and a
correspondingly lower temporal resolution (the authors report
acquisition of an image every six heart beats) are of practical
advantage. In fact, this forces them to determine blood flow
indirectly with the Kety model by measuring the product of
extraction efficiency (E) and myocardial blood flow (F) and to
assume that the extraction efficiency is unchanged for different
pathologies. The Kety model is most suitable for modeling the
kinetics of freely diffusible tracers because the extraction efficiency
can then be set to unity. For extracellular MRI contrast agents such
as Gd-DTPA, which are barrier-limited, the assumption that the
extraction remains constant is controversial. Several investigators
have shown that E varies with flow, and between normal and
ischemic/reperfused myocardium by as much as 100% (3,4). Data
by Watson et al. (5) comparing the FE product with blood flows
measured by positron emission tomography (PET) show that at
low flows the FE product is rather insensitive to changes in flow.
Furthermore, E is generally not constant during distribution of a
tracer, and the choice of an E value is by no means unambiguous.
The fact that the reported values of the perfusion reserve index,
calculated with the assumption of a constant E, agree in normal
healthy volunteers with previous PET studies is not sufficient to
validate the application of the Kety model in patients.
Although Cullen et al. (1) describe their MRI measurements as
first-pass studies, this does not seem to be appropriate when
images are acquired every six heart beats. In fact, the Kety model
may not fit well with data acquired in a true first-pass study owing
to the initially low extraction of contrast agent during wash-in.
The authors’ criticism (p. 1391) of previous first-pass studies (6)
because of use of a fast bolus injection is misleading. The perfusion
reserve estimate obtained in patients with microvascular dysfunc-
tion with such MRI first-pass studies was validated by comparison
to the coronary flow reserve (6). It remains to be shown that a
perfusion reserve index derived with the Kety model corresponds
under different pathophysiological conditions to the myocardial
blood flow reserve. In our opinion the first-pass technique is
preferred to determine myocardial blood flow and the myocardial
blood flow reserve.
Michael Jerosch-Herold, PhD
Norbert M. Wilke, MD
Arthur E. Stillman, MD, PhD
Department of Radiology
University of Minnesota
Minneapolis, MN
E-mail: jeros001@tc.umn.edu.
PII S0735-1097(00)00686-0
REFERENCES
1. Cullen JHS, Horsfield MA, Reek CR, et al. A myocardial perfusion
reserve index in humans using first-pass contrast-enhanced magnetic
resonance imaging. J Am Coll Cardiol 1999;33:1386–94.
2. Wilke N, Jerosch-Herold M. Assessing myocardial perfusion in coro-
nary artery disease with magnetic resonance first-pass imaging. Cardiol
Clin 1998;16:227–46.
3. Patel PP, Koppenhafer SL, Scholz TD. Measurement of kinetic
perfusion parameters of gadoteridol in intact myocardium: effects of
ischemia/reperfusion and coronary vasodilation. Magn Reson Imaging
1995;13:799–806.
4. Tong CY, Prato FS, Wisenberg F, et al. Measurement of the extraction
efficiency and distribution volume for Gd-DTPA in normal and
diseased canine myocardium. Magn Reson Med 1993;30:337–46.
5. Watson MT, Lorenz CH, Delbeke DJ, et al. Quantification of regional
myocardial perfusion: a comparison of contrast-enhanced magnetic
resonance imaging and positron emission tomography (abstr). In:
Proceedings of 12th Annual Scientific Meeting, Society of Magnetic
Resonance, Berkeley, California, 1993:636.
6. Wilke N, Jerosch-Herold M, Wang Y, et al. Myocardial perfusion
reserve: assessment with multisection, quantitative, first-pass MR im-
aging. Radiology 1997;204:373–84.
REPLY
I would like to respond to several issues raised by the letter of
Jerosch-Herold et al. First, I do not purport that a lower temporal
resolution of an image every six heart beats used in our study (1)
confers an advantage. This is a clear compromise between having
more slices and less data points on the first-pass transit curves,
which was necessitated by the hardware constraints we had at the
inception of this study. Although the use of an inversion-recovery
sequence results in relatively prolonged image acquisition times
even with the fastest magnetic resonance imaging (MRI) scanners,
the images are stable and of good quality for analysis. This is in
contrast to the saturation-recovery sequences used by Jerosch-
Herold (2), which may allow more of the heart to be imaged in less
time but in which the images are often of poor quality and subject
to artefacts. However, the slower injection technique used in our
study is an advantage over the power injections into the right
subclavian vein reported in other studies (2); this is because a
relatively invasive subclavian line is needed, which is less attractive
for patient and operator. Also, a power injector is required, which
is safe with magnetic fields and correspondingly expensive, whereas
our technique can be administered manually through a peripheral
vein.
Second, the question of whether the extraction efficiency (E)
remains constant or varies with myocardial flow (F) is controversial
and as yet remains a subject for further research. In support of
using the EF product (K1) for estimating flow, a recent study by
Vallee et al. (3) in a canine occluded coronary artery model
demonstrated that F measured with microspheres had a linear fit to
K1 for Gd-DTPA, (r 5 0.88). However, as the behavior of E is
uncertain at differing flow rates, the term “myocardial perfusion
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